Concepts (67)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiphospholipid Syndrome | 2 | 2021 | 25 | 1.440 |
Why?
|
| Thromboplastin | 3 | 2020 | 21 | 1.040 |
Why?
|
| beta 2-Glycoprotein I | 2 | 2020 | 10 | 0.880 |
Why?
|
| Antibodies, Antiphospholipid | 5 | 2021 | 29 | 0.730 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2019 | 2 | 0.670 |
Why?
|
| Platelet Aggregation | 1 | 2019 | 127 | 0.660 |
Why?
|
| Epitopes | 1 | 2019 | 146 | 0.640 |
Why?
|
| Blood Platelets | 1 | 2019 | 284 | 0.610 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 626 | 0.580 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 511 | 0.570 |
Why?
|
| Blood Coagulation | 3 | 2021 | 123 | 0.370 |
Why?
|
| Thrombosis | 2 | 2021 | 218 | 0.200 |
Why?
|
| Monocytes | 2 | 2019 | 210 | 0.190 |
Why?
|
| Endothelial Protein C Receptor | 1 | 2021 | 1 | 0.190 |
Why?
|
| Monoglycerides | 1 | 2021 | 7 | 0.190 |
Why?
|
| Antigen Presentation | 1 | 2021 | 76 | 0.180 |
Why?
|
| Autoantibodies | 2 | 2021 | 434 | 0.180 |
Why?
|
| Autoimmunity | 1 | 2021 | 118 | 0.180 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 45 | 0.170 |
Why?
|
| Lysophospholipids | 1 | 2021 | 209 | 0.170 |
Why?
|
| Everolimus | 1 | 2019 | 26 | 0.170 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2019 | 80 | 0.160 |
Why?
|
| Complement C5 | 1 | 2018 | 3 | 0.160 |
Why?
|
| Sirolimus | 1 | 2019 | 118 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 118 | 0.160 |
Why?
|
| Endothelial Cells | 1 | 2021 | 384 | 0.150 |
Why?
|
| Education, Nursing, Baccalaureate | 2 | 2015 | 50 | 0.150 |
Why?
|
| Complement C3 | 1 | 2018 | 101 | 0.150 |
Why?
|
| Gene Expression | 1 | 2020 | 770 | 0.150 |
Why?
|
| Cells, Cultured | 2 | 2019 | 2673 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 125 | 0.140 |
Why?
|
| Faculty, Nursing | 1 | 2016 | 29 | 0.130 |
Why?
|
| Schools, Nursing | 1 | 2016 | 19 | 0.130 |
Why?
|
| Career Mobility | 1 | 2016 | 34 | 0.130 |
Why?
|
| Personnel Loyalty | 1 | 2015 | 5 | 0.130 |
Why?
|
| Personnel Turnover | 1 | 2015 | 14 | 0.130 |
Why?
|
| Internship, Nonmedical | 1 | 2015 | 19 | 0.130 |
Why?
|
| Simulation Training | 1 | 2015 | 49 | 0.120 |
Why?
|
| Mice | 3 | 2021 | 8474 | 0.120 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 756 | 0.120 |
Why?
|
| Students, Nursing | 1 | 2015 | 101 | 0.120 |
Why?
|
| Humans | 8 | 2021 | 68618 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2019 | 2689 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2015 | 502 | 0.110 |
Why?
|
| Animals | 4 | 2021 | 20881 | 0.100 |
Why?
|
| Staff Development | 2 | 2016 | 35 | 0.060 |
Why?
|
| Embryo Loss | 1 | 2021 | 17 | 0.050 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2021 | 17 | 0.050 |
Why?
|
| Endosomes | 1 | 2021 | 45 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 166 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2021 | 156 | 0.040 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2021 | 183 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2019 | 161 | 0.040 |
Why?
|
| Videotape Recording | 1 | 2015 | 43 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2015 | 62 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2015 | 123 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2018 | 1692 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 281 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2550 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 652 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 2791 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1054 | 0.020 |
Why?
|
| Male | 3 | 2019 | 37321 | 0.020 |
Why?
|
| Female | 3 | 2019 | 38074 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2015 | 657 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 21403 | 0.020 |
Why?
|
| Middle Aged | 1 | 2015 | 21147 | 0.010 |
Why?
|